Patient-reported Outcomes in Children with Sickle Cell Disease at Presentation for an Acute Pain Episode

Overview

Journal Blood Adv

Specialty Hematology

Date 2022 Nov 2

PMID 36322873

Authors

Nitya Bakshi

Zihao Liu

Scott Gillespie

Rohali Keesari

Deborah Leake

Kirshma Khemani

Polly Kumari

Chris A Rees

Carlton Dampier

Claudia R Morris

Affiliations

Soon will be listed here.

References

Tripathi A, Jerrell J, Stallworth J . Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Pediatr Blood Cancer. 2010; 56(1):90-4. DOI: 10.1002/pbc.22822. View

Badawy S, Thompson A, Lai J, Penedo F, Rychlik K, Liem R . Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016; 64(6). DOI: 10.1002/pbc.26369. View

Singh A, Panepinto J . Clinical meaning of PROMIS pain domains for children with sickle cell disease. Blood Adv. 2019; 3(15):2244-2249. PMC: 6693018. DOI: 10.1182/bloodadvances.2019000381. View

Dampier C, Barry V, Gross H, Lui Y, Thornburg C, DeWalt D . Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease. Pediatr Blood Cancer. 2016; 63(6):1031-7. PMC: 4833539. DOI: 10.1002/pbc.25944. View

Bakshi N, Cooley A, Ross D, Hawkins L, Sullivan M, Astles R . A pilot study of the acceptability, feasibility and safety of yoga for chronic pain in sickle cell disease. Complement Ther Med. 2021; 59:102722. PMC: 8284565. DOI: 10.1016/j.ctim.2021.102722. View

Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G . A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015; 126(14):1651-7. PMC: 4591790. DOI: 10.1182/blood-2015-05-647107. View

Krishnamurti L, Neuberg D, Sullivan K, Kamani N, Abraham A, Campigotto F . Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. Am J Hematol. 2019; 94(4):446-454. PMC: 6542639. DOI: 10.1002/ajh.25401. View

Badawy S, Thompson A, Holl J, Penedo F, Liem R . Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr Hematol Oncol. 2019; 35(5-6):297-308. DOI: 10.1080/08880018.2018.1505988. View

Cunningham N, Kashikar-Zuck S, Mara C, Goldschneider K, Revicki D, Dampier C . Development and validation of the self-reported PROMIS pediatric pain behavior item bank and short form scale. Pain. 2017; 158(7):1323-1331. PMC: 5996986. DOI: 10.1097/j.pain.0000000000000914. View

10.

Singh S, Bakshi N, Mahajan P, Morris C . What is the future of patient-reported outcomes in sickle-cell disease?. Expert Rev Hematol. 2020; 13(11):1165-1173. PMC: 7722233. DOI: 10.1080/17474086.2020.1830370. View

11.

Singh A, Dasgupta M, Simpson P, Brousseau D, Panepinto J . Can PROMIS domains of pain and physical functioning detect changes in health over time for children with sickle cell disease?. Pediatr Blood Cancer. 2020; 67(5):e28203. DOI: 10.1002/pbc.28203. View

12.

Dampier C, Jaeger B, Gross H, Barry V, Edwards L, Lui Y . Responsiveness of PROMIS® Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery. Pediatr Blood Cancer. 2016; 63(6):1038-45. PMC: 5055833. DOI: 10.1002/pbc.25931. View

13.

Bakshi N, Ross D, Krishnamurti L . Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease. J Pain Res. 2018; 11:313-318. PMC: 5810514. DOI: 10.2147/JPR.S150065. View

14.

Steinberg M, Barton F, Castro O, Pegelow C, Ballas S, Kutlar A . Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003; 289(13):1645-51. DOI: 10.1001/jama.289.13.1645. View

15.

Rees C, Brousseau D, Cohen D, Villella A, Dampier C, Brown K . Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial. Trials. 2023; 24(1):538. PMC: 10433602. DOI: 10.1186/s13063-023-07538-z. View

16.

Panepinto J, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G . Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module. Health Qual Life Outcomes. 2017; 15(1):124. PMC: 5468970. DOI: 10.1186/s12955-017-0700-2. View

17.

Singh A, Dasgupta M, Simpson P, Panepinto J . Use of the new pediatric PROMIS measures of pain and physical experiences for children with sickle cell disease. Pediatr Blood Cancer. 2019; 66(5):e27633. DOI: 10.1002/pbc.27633. View

18.

Farrell A, Panepinto J, Carroll C, Darbari D, Desai A, King A . End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Adv. 2019; 3(23):3982-4001. PMC: 6963237. DOI: 10.1182/bloodadvances.2019000882. View

19.

Reyes L, Figueroa J, Leake D, Khemani K, Kumari P, Bakshi N . Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: A randomized placebo-controlled trial in progress. Am J Hematol. 2021; 97(1):E21-E24. PMC: 8722015. DOI: 10.1002/ajh.26396. View

20.

Platt O, Thorington B, Brambilla D, Milner P, Rosse W, Vichinsky E . Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991; 325(1):11-6. DOI: 10.1056/NEJM199107043250103. View